Thus, in the clinical setting, drugs that can control IDO1 activity [68] should potentiate the Fas-dependent NK-cell-mediated killing of NB cells treated with cytokines such as IFNγ and TNFα. The gene discussed is FAS; the disease is neuroblastoma.